Phage therapy program
TechnoPhage
| Status | Provider-listed inquiry route |
|---|---|
| Type | Company |
| Location | Lisbon; Portugal |
| Entry review | 2026-10-03 |
Access and enquiries
| How to enquire | Official TP-102 expanded-access policy accepts requests only from treating physicians, via expandedaccess@technophage.pt or the company form; case review, suitable supply and local approvals required. |
|---|---|
| Areas of work | TP-102 investigational topical phages for infected diabetic foot/nonhealing wounds involving S. aureus, P. aeruginosa or A. baumannii; separate TP-122 respiratory development. |
| International access | Expanded-access policy requires compliance with the requesting country laws; no blanket nonresident or worldwide acceptance. |
What to confirm
- Expanded access is discretionary, investigational and distinct from trial enrollment.
- June 2026 approval announcement does not resolve current Portuguese CTIS suspension.
- Regulatory approval and actual recruitment are separate states.
Related studies(4)
TP-122_101A
Not yet recruiting
Recorded program–study link. Website
REVERSE
Completed
Recorded program–study link. Website
REVERSE2
Completed
Recorded program–study link. Website
RECOVER
Not authorised
Recorded program–study link. Website
Sources and updates
Entry reviewed . This is the date of our source review, not a confirmation of availability today.
- TechnoPhage expanded access
- TechnoPhage TP-122 European authorization announcement
- ClinicalTrials.gov NCT05948592
- ClinicalTrials.gov NCT06370598
- CTIS 2025-521533-85-00
AI helped us research this directory. Details may be wrong or out of date. Confirm availability with the clinic or study team. Suggest a correction.
| Program ID | eu-technophage |
|---|